Log In

Forgot Password?
Create New Account

Loading... please wait

2024 Annual Meeting | C166 - Myelopathies: Recognizing and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes

Wednesday 04/17/24
01:00 PM - 03:00 PM MDT Add To Calendar
Colorado Convention Center | Bluebird 1C
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Eoin P. Flanagan, MBBCh, FAAN
General Neurology
Participants should be able to navigate more easily towards the correct diagnosis and avoid diagnostic pitfalls in a patient presenting with myelopathy. Clinical and radiologic pearls will assist the general neurologist in recognizing the cause of myelopathy and ordering the correct investigations to confirm the diagnosis. Attendees will be more aware of specific advances in the field of autoimmune myelopathies (e.g., myelin-oligodendrocyte glycoprotein-IgG associated myelitis) and acute and chronic management of myelopathy (e.g., utility of plasma exchange in a patient with a severe myelitis from aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder).
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice
Intermediate
Neurohospitalist
Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student
Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:05 PM MDT Speaker Introduction
Eoin P. Flanagan, MBBCh, FAAN
01:05 PM - 01:40 PM MDT Speaker Inflammatory Myelopathies: Clinical, Serologic, and Treatment Pearls
Jacqueline Palace
01:40 PM - 02:15 PM MDT Speaker Radiologic Pearls in Vascular and Inflammatory Myelopathies and Their Mimics
Eoin P. Flanagan, MBBCh, FAAN
02:15 PM - 02:50 PM MDT Speaker Clinical Pearls in Vascular Myelopathy
Neeraj Kumar, MD
02:50 PM - 03:00 PM MDT Q&A Questions & Answers
Eoin P. Flanagan, MBBCh, FAAN, Neeraj Kumar, MD
Faculty Disclosures
Eoin P. Flanagan, MBBCh, FAAN The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.
Neeraj Kumar, MD Dr. Kumar has nothing to disclose.
Jacqueline Palace Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck Serono, Medimmune, Argenx, Janssen, Mitsubushi, UCB, Roche, Novartis, Amplo, Alexion, Chugai, Sanofi. Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx, Sanofi. Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Roche, UCB, Alexion, Chugai. Dr. Palace has stock in Astra Zenica. The institution of Dr. Palace has received research support from Roche, AMPLO, Alexion, UCB,.Meddimune, argenx. Dr. Palace has received intellectual property interests from a discovery or technology relating to health care.